ERBB2 and breast cancer: In vitro experiments have shown that ER+/HER2- BC cells are sensitive to palbociclib under conditions of enhanced aerobic glycolysis whilst ER+/HER2+ cells show enhanced glycolytic catabolism with the development of palbociclib resistance. These metabolic phenotypes may have potential prognostic value (101).